Replies to post #518765 on Anavex Life Sciences Corp (AVXL)

[Lacey1]

Thankyou for providing this. I also agree 1st pill to market wins the most. Wasn't aware how close Annovis is to completion of phase 3 trial. Does anavex even have a shot at FDA approval with all data to date presented. Even if we agree to start a trial, can we get a conditional approval by year end and probably before the elections.

[sliceanddice59]

I appreciate your post. I hope Buntanetap is successful. I think that, if the idea that combination therapy will be needed in the end is correct, there will be room in the marketplace for a number of drugs including Blarcamesine (S1 receptor agonist/autophagy enhancer/improving mitochondrial function/reduction of tau and amyloid ….), Cognition Therapeutic’s drug (S2 receptor agonist), and even the MABs, as well as Buntanetap. Ì own stock in Anavex, Annovis and Cognition. I hope I’m right and not triply wrong.

[Foodman1291]

Abe
Always enjoy and respect your posts. However, with a little concern I had a conversation regarding Annovis with Chatgbt and found them waning regarding their trial endpoint achievement, safety, efficacy results so far and none of their small trials exceeded 6 months. They appear to be well behind us in almost every category and well behind in timeline, finances and any meaningful accomplishments or data depth, genome research
or anything approaching peer review status. In addition, there is no evidence of any brain preservation at all. Many rounds of dilution as well.
They might have a pill but that’s about it. Please keep posting as I always look forward to your insights and perspective.

[Foodman1291]

Abe
Always enjoy and respect your posts. However, with a little concern I had a conversation regarding Annovis with Chatgbt and found them waning regarding their trial endpoint achievement, safety, efficacy results so far and none of their small trials exceeded 6 months. They appear to be well behind us in almost every category and well behind in timeline, finances and any meaningful accomplishments or data depth, genome research
or anything approaching peer review status. In addition, there is no evidence of any brain preservation at all. Many rounds of dilution as well.
They might have a pill but that’s about it. Please keep posting as I always look forward to your insights and perspective.

[Bourbon_on_my_cornflakes]

Annovis Bio started recruiting for their pivotal P3 AD trial in February, 2025. They are 90% complete in their enrollment (n=760). Yes. It's taken them 1 1/2 years to get to this point! There are two markets in the AD field. Symptomatic = $7 Billion...and Disease Modifying = $100 Billion Annovis Bio will be filing an NDA for both markets.

ANVS is clearly in the drivers seat now. Mgt that can at least get trials running. A chance to make the big alz score. Meanwhile AVXL cant even issue its financials or chart a path forward. Clearly the only option now for AVXL is to sell the company to someone competent ( fi the science actually works) So sad.

(Bourbon, in particular, was extremely pissed off...chalking it up to another lost opportunity due to Missling's glacial pace)
So, based on Jim Cramer's comment: "The first one with a pill, wins!".